Work

Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer

Year: 2019

Type: article

Abstract: This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced bladder cancer and subsequent changes in practice.

Source: JAMA

DOI: 10.1001/jama.2019.10650

Authors: Ravi B. Parikh, Blythe J. S. Adamson, Sean Khozin, Matthew D. Galsky, Shrujal S. Baxi, Aaron Cohen, Ronac Mamtani

Institutions: Abramson Cancer Center, University of Pennsylvania, Flatiron Health (United States), United States Food and Drug Administration, Tisch Cancer Institute

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Conquer Cancer Foundation, Flatiron Health, National Institutes of Health, National Cancer Institute

Awards: G388955488, G9000072716, G9000222654, Cancer Center Research Training Program

OpenAlex ID: W2976496957

FWCI: 4.097

Cites: 7

Cited by: 21

Related to: 10